Tag:

Biogen Idec

Latest Headlines

Latest Headlines

Biogen Idec spotlights Eloctate manufacturing in video targeted at consumers

Biogen Idec has released a four-minute video via the Twitter sponsored feed that explains all of the manufacturing steps it goes through in making and purifying the treatment for hemophilia A.

Biogen Idec quietly carves out a leading role in developing gene therapy for hemophilia

Biogen Idec and its newly named in-house expert Olivier Danos have executed a research deal with the San Raffaele-Telethon Institute for Gene Therapy to develop what they believe promises to be a durable treatment for hemophilia.

Biogen taps Google's data analytics skills for MS research

The Google X lab that spawned smart contact lenses and self-driving cars is teaming up with Biogen Idec to unravel patient-to-patient variation in the progression of multiple sclerosis.

Samsung Bioepis advances its Enbrel biosimilar to an EMA review

The Marketing Authorization Application for SB4, the Enbrel (etanercept) biosimilar candidate developed by Korean biopharmaceutical company Samsung Bioepis, has been validated and accepted for review by the European Medicines Agency. It will become the first Enbrel biosimilar subjected to regulatory review in the European Union.

Google, Biogen team up on MS research: report

Looking for some insights into the way that environment and biology influence the development of multiple sclerosis, Biogen Idec will team up with Google to sift through a mountain of data on the topic, according to a report from Bloomberg.

Biogen Idec grabs Convergence, neuropathic pain portfolio in $675M buyout

Back last summer the U.K.'s Convergence Pharmaceuticals, a spinout from GlaxoSmithKline, was feeling bullish about its prospects after it wrapped up a positive mid-stage study of its lead drug for neuropathic pain. But rather than take the risky step of mounting an IPO--still a tough prospect in the U.K.--Convergence instead opted to sell to Biogen Idec, which is using the acquisition to beef up its pipeline in the field.

Biogen Idec inks $30M genetic R&D alliance with Columbia University

Some of the cash will go toward creating a sequencing and analysis center at Columbia to support collaborative research.

UPDATED: Biogen Idec's remyelination drug raises hopes--and fears--in PhII

Shares of Biogen Idec were buoyed this morning after the big biotech highlighted positive data from its mid-stage study of anti-LINGO-1, a closely watched drug that raises the potential for spurring remyelination--repairing the damage done by diseases like multiple sclerosis. But a careful second look at the results also underscores just how challenging this development program is for Biogen Idec.

'Futuristic' treatments come to fruition with cell and gene therapies

The world of gene therapy--in which single-dose treatments correct debilitating defects--enjoyed something of a renaissance in 2014. Strong clinical results from leaders in the once-maligned field spurred renewed optimism, helping a new generation of startups secure millions in venture financing to develop their next-generation approaches to the field.

Biogen barrels toward Alzheimer's Phase III after a promising early signal

Biogen Idec is heralding hope in one of the industry's toughest fields, plotting a late-stage trial for an Alzheimer's disease treatment after charting some surprising positive results in an early study.